Walleye Capital LLC Decreases Holdings in Catalent, Inc. (NYSE:CTLT)

Walleye Capital LLC reduced its holdings in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 16.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 242,339 shares of the company's stock after selling 48,565 shares during the period. Walleye Capital LLC owned approximately 0.13% of Catalent worth $14,678,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board raised its position in shares of Catalent by 16.2% in the third quarter. Public Sector Pension Investment Board now owns 7,910 shares of the company's stock worth $479,000 after acquiring an additional 1,100 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Catalent by 4.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,024,240 shares of the company's stock worth $62,038,000 after purchasing an additional 45,564 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Catalent by 12.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,982 shares of the company's stock worth $2,301,000 after purchasing an additional 4,088 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company's stock valued at $83,733,000 after purchasing an additional 863,624 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Catalent by 9.3% in the third quarter. BNP Paribas Financial Markets now owns 267,219 shares of the company's stock valued at $16,185,000 after buying an additional 22,785 shares in the last quarter.

Catalent Price Performance

Catalent stock traded up $0.11 during midday trading on Friday, reaching $61.11. The company's stock had a trading volume of 771,192 shares, compared to its average volume of 2,030,913. The firm has a market capitalization of $11.09 billion, a PE ratio of -27.04, a P/E/G ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50. The stock's 50 day simple moving average is $59.90 and its 200 day simple moving average is $58.47. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the prior year, the firm posted ($0.10) EPS. The firm's quarterly revenue was up 4.2% on a year-over-year basis. On average, equities research analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Robert W. Baird reaffirmed a "neutral" rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. William Blair reiterated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, StockNews.com lowered Catalent from a "hold" rating to a "sell" rating in a report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to MarketBeat.com, Catalent has an average rating of "Hold" and a consensus target price of $63.40.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,114 shares of company stock valued at $305,931. Insiders own 0.31% of the company's stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.